OTCPK:BIUP.F

Stock Analysis Report

Executive Summary

Biom'Up S.A. designs, develops, manufactures, and sells collagen-based absorbable medical devices for biosurgery primarily in France.

Snowflake

Fundamentals

Imperfect balance sheet with limited growth.

Risks

  • Biom'Up is covered by less than 3 analysts.

Share Price & News

How has Biom'Up's share price performed over time and what events caused price changes?


Latest Share Price and Events


Market Performance


7 Day Return

0%

OTCPK:BIUP.F

-0.9%

US Medical Equipment

1.3%

US Market


1 Year Return

n/a

OTCPK:BIUP.F

9.1%

US Medical Equipment

2.0%

US Market

No trading data on BIUP.F.

No trading data on BIUP.F.


Share holder returns

BIUP.FIndustryMarket
7 Day0%-0.9%1.3%
30 Day0%0.7%3.9%
90 Dayn/a4.4%3.4%
1 Yearn/a10.0%9.1%4.2%2.0%
3 Yearn/a70.7%65.5%47.2%37.6%
5 Yearn/a130.7%104.3%60.5%42.9%

Price Volatility Vs. Market

How volatile is Biom'Up's share price compared to the market and industry in the last 5 years?


Simply Wall St News

No news available

Valuation

Is Biom'Up undervalued based on future cash flows and its price relative to the stock market?

0.66x

Price to Book (PB) ratio


Intrinsic Value Based on Future Cash Flows

Unable to calculate intrinsic value for Biom'Up to establish if it is available at moderate discount.

Unable to calculate intrinsic value for Biom'Up to establish if it is available at substantial discount.


Price Based on Earnings

Biom'Up is loss making, we can't compare its value to the US Medical Equipment industry average.

Biom'Up is loss making, we can't compare the value of its earnings to the United States of America market.


Price Based on Expected Growth

Unable to calculate PEG ratio for Biom'Up, we can't assess if its growth is good value.


Price Based on Value of Assets

Biom'Up is good value based on assets compared to the US Medical Equipment industry average.


Next Steps

Future Growth

How is Biom'Up expected to perform in the next 1 to 3 years based on estimates from 2 analysts?

35.0%

Forecasted annual earnings growth


Earnings and Revenue Growth Estimates


Future Annual Growth Analysis

Biom'Up's revenue is expected to grow significantly at over 20% yearly.

Biom'Up is not considered high growth as it is expected to be loss making for the next 1-3 years.

Biom'Up's revenue growth is expected to exceed the United States of America market average.

Unable to compare Biom'Up's earnings growth to the United States of America market average as it is expected to be loss making during the next 1-3 years.

Unable to compare Biom'Up's earnings growth to the low risk savings rate as it is expected to be loss making during the next 1-3 years.


Earnings per Share Growth Estimates


Future Return on Equity

Unable to establish if Biom'Up will efficiently use shareholders’ funds in the future without estimates of Return on Equity.


Next Steps

Past Performance

How has Biom'Up performed over the past 5 years?

-29.8%

Last years earnings growth


Earnings and Revenue History


Past Earnings Growth Analysis

Biom'Up does not make a profit and there is insufficient past data to establish if their 5 year on year earnings growth rate was positive.

Unable to compare Biom'Up's 1-year earnings growth to the 5-year average as it is not currently profitable.

Unable to compare Biom'Up's 1-year growth to the US Medical Equipment industry average as it is not currently profitable.


Return on Equity

It is difficult to establish if Biom'Up has efficiently used shareholders’ funds last year (Return on Equity greater than 20%) as it is loss-making.


Return on Assets

It is difficult to establish if Biom'Up has efficiently used its assets last year compared to the US Medical Equipment industry average (Return on Assets) as it is loss-making.


Return on Capital Employed

It is difficult to establish if Biom'Up improved its use of capital last year versus 3 years ago (Return on Capital Employed) as it is currently loss-making.


Next Steps

Financial Health

How is Biom'Up's financial position?


Financial Position Analysis

Biom'Up is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.

Biom'Up's cash and other short term assets cover its long term commitments.


Debt to Equity History and Analysis

Biom'Up's level of debt (111.2%) compared to net worth is high (greater than 40%).

Unable to establish if Biom'Up's debt level has increased without past 5-year debt data.


Balance Sheet

Low level of unsold assets.

Debt is covered by short term assets, assets are 1.3x debt.


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Biom'Up has less than a year of cash runway based on current free cash flow.

Biom'Up has less than a year of cash runway if free cash flow continues to grow at historical rates of 34.7% each year.


Next Steps

Dividend

What is Biom'Up's current dividend yield, its reliability and sustainability?


Dividend Yield and Payments Analysis

Unable to evaluate Biom'Up's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.

Unable to evaluate Biom'Up's dividend against the top 25% market benchmark as the company has not reported any payouts.

Unable to perform a dividend volatility check as Biom'Up has not reported any payouts.

Unable to verify if Biom'Up's dividend has been increasing as the company has not reported any payouts.


Current Payout to Shareholders

Unable to calculate sustainability of dividends as Biom'Up has not reported any payouts.


Future Payout to Shareholders

No need to calculate the sustainability of Biom'Up's dividends in 3 years as they are not expected to pay a notable one for United States of America.


Next Steps

Management

What is the CEO of Biom'Up's salary, the management and board of directors tenure and is there insider trading?

0.7yrs

Average management tenure


CEO

Jan Ohrstrom (62yo)

0.3yrs

Tenure

€93,902

Compensation

Dr. Jan K. Ohrstrom , M.D., has been the Executive Chairman and CEO at Biom'Up S.A. since May 31, 2019. He served as Chairman of the Board of Biom'Up S.A. since from 2015 to May 31, 2019. He serves as Chie ...


CEO Compensation Analysis

Jan's remuneration is lower than average for companies of similar size in United States of America.

Jan's compensation has been consistent with company performance over the past year, both up more than 20%.


Management Age and Tenure

0.7yrs

Average Tenure

The average tenure for the Biom'Up management team is less than 2 years, this suggests a new team.


Board Age and Tenure

1.2yrs

Average Tenure

54yo

Average Age

The average tenure for the Biom'Up board of directors is less than 3 years, this suggests a new board.


Insider Trading

No 3 month open market individual insider trading information.


Ownership Breakdown


Management Team

  • Jean-Yves Quentel

    Chief Financial Officer

    • Tenure: 0yrs
  • Jan Ohrstrom (62yo)

    Executive Chairman & CEO

    • Tenure: 0.3yrs
    • Compensation: €93.90k
  • Cecile Ferracci (50yo)

    Global Vice President of Marketing

    • Tenure: 1.8yrs
  • Jean-Luc Imbert

    Chief Operating Officer

    • Tenure: 0yrs
  • Valérie Centis

    Chief Scientific Officer & Executive Vp

    • Tenure: 0yrs
  • George Makhoul

    Chief Commercial Officer of United States

    • Tenure: 0.7yrs

Board Members

  • Jan Ohrstrom (62yo)

    Executive Chairman & CEO

    • Tenure: 0.3yrs
    • Compensation: €93.90k
  • Karl Naegler (46yo)

    Director

    • Tenure: 0yrs
  • Thibaut Roulon

    • Tenure: 1.2yrs
  • Erin Gainer (45yo)

    Independent Director

    • Tenure: 0yrs
    • Compensation: €23.72k
  • Marie-Claire Janailhac-Fritsch (64yo)

    Vice Chairman of the Board

    • Tenure: 0yrs
    • Compensation: €46.28k
  • Peter Byloos

    Independent Director

    • Tenure: 1yrs
    • Compensation: €8.24k
  • Abbas Ardehali

    Independent Director

    • Tenure: 0yrs
    • Compensation: €19.40k
  • Janice Hogan

    Non-Voting Observer

    • Tenure: 1.2yrs

Company Information

Biom'Up S.A.'s company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Biom'Up S.A.
  • Ticker: BIUP.F
  • Exchange: OTCPK
  • Founded: 2005
  • Industry: Health Care Supplies
  • Sector: Healthcare
  • Market Cap: €17.106m
  • Listing Market Cap: €18.943m
  • Shares outstanding: 14.25m
  • Website: https://www.biomup.com

Number of Employees


Location

  • Biom'Up S.A.
  • Parc Technologique de Lyon
  • 8, allée Irène Joliot Curie
  • Saint-Priest
  • Rhône-Alpes
  • 69800
  • France

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
BUPENXTPA (Euronext Paris)YesCommon SharesFREUROct 2017
BIUP.FOTCPK (Pink Sheets LLC)YesCommon SharesUSUSDOct 2017

Biography

Biom'Up S.A. designs, develops, manufactures, and sells collagen-based absorbable medical devices for biosurgery primarily in France. It offers products under the HEMOBLAST and HEMOSNOW names for surgical  ...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2019/09/16 00:34
End of Day Share Price2019/06/25 00:00
Earnings2018/12/31
Annual Earnings2018/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.